Chemed Corp (CHE)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
- Symbol
- CHE
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Market cap
- $6.51B
- 52 week range
- 365.21 - 557
Valuation
- Share price
- $498.09 (close of 2026-09-23)
- P/E (TTM)
- 25.03x
- Price to book
- 7.84x
- Price to free cash flow
- 20.12x
- Enterprise value
- $6.76B
- Book value per share
- $63.54
Price performance
| Period | Change |
|---|
| 1 day | -0.31% |
| 5 days | -1.65% |
| 1 month | -7.86% |
| 3 months | +12.15% |
| 6 months | +33.39% |
| Year to date | +16.41% |
| 1 year | +9.74% |
| 3 years | -2.70% |
| 5 years | +5.97% |
| 10 years | +252.53% |
| All time | +5434.33% |
Profitability and growth
- Return on equity
- 27.08%
- Return on invested capital
- 23.62%
- Return on assets
- 17.24%
- Return on capital employed
- 27.04%
- Gross margin
- 32.54%
- Net margin
- 10.48%
- EBITDA margin
- 15.93%
- Revenue growth
- 65.25%
- Net income growth
- -12.17%
- Free cash flow growth
- -11.55%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 4.97%
- Current ratio
- 0.91x
- Net debt to EBITDA
- 0.59x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $2.53B
- Cost of revenue
- $1.71B
- Gross profit
- $823.18M
- EBITDA
- $403.09M
- Net income
- $265.24M
- Earnings per share
- $18.42
- Interest expense
- $1.75M
- Shares outstanding
- 14.40M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $2.53B | $823.18M | $265.24M | $18.42 |
| 2024-12-31 | $1.53B | $-45.96M | $302.00M | $20.10 |
| 2023-12-31 | $1.32B | $-150.54M | $272.51M | $18.11 |
| 2022-12-31 | $1.20B | $-168.31M | $249.62M | $16.72 |
| 2021-12-31 | $1.26B | $-108.21M | $268.55M | $17.14 |
| 2020-12-31 | $1.33B | $-43.53M | $319.47M | $20.02 |
| 2019-12-31 | $1.28B | $-39.94M | $219.92M | $13.77 |
| 2018-12-31 | $1.20B | $-30.08M | $205.54M | $12.80 |
| 2017-12-31 | $1.67B | $516.19M | $98.18M | $6.11 |
| 2016-12-31 | $1.58B | $461.45M | $108.74M | $6.64 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 32.54% | 10.48% | 27.08% | 23.62% |
| 2024-12-31 | -3.00% | 19.73% | 26.99% | 24.88% |
| 2023-12-31 | -11.45% | 20.72% | 24.60% | 26.72% |
| 2022-12-31 | -14.01% | 20.77% | 31.25% | 27.11% |
| 2021-12-31 | -8.58% | 21.29% | 43.09% | 28.59% |
| 2020-12-31 | -3.26% | 23.94% | 35.45% | 35.83% |
| 2019-12-31 | -3.12% | 17.17% | 30.27% | 23.03% |
| 2018-12-31 | -2.51% | 17.16% | 34.76% | 31.02% |
| 2017-12-31 | 30.97% | 5.89% | 18.17% | 14.96% |
| 2016-12-31 | 29.26% | 6.90% | 20.75% | 17.88% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $74.52M | - |
| 2024-12-31 | $178.35M | - |
| 2023-12-31 | $263.96M | - |
| 2022-12-31 | $74.13M | $92.50M |
| 2021-12-31 | $32.90M | $185.00M |
| 2020-12-31 | $162.68M | - |
| 2019-12-31 | $6.16M | $90.00M |
| 2018-12-31 | $4.83M | $89.20M |
| 2017-12-31 | $11.12M | $91.20M |
| 2016-12-31 | $15.31M | $100.00M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $325.48M | $38.68M |
| 2024-12-31 | $367.97M | $52.11M |
| 2023-12-31 | $273.44M | $40.79M |
| 2022-12-31 | $252.56M | $33.61M |
| 2021-12-31 | $249.92M | $31.42M |
| 2020-12-31 | $430.46M | $26.80M |
| 2019-12-31 | $248.23M | $21.34M |
| 2018-12-31 | $234.27M | $19.23M |
| 2017-12-31 | $98.19M | $16.26M |
| 2016-12-31 | $95.62M | $13.77M |
Dividend history
- Most recent payment
- 2026-08-17
- Paid in the last twelve months
- $2.50
| Payment date | Dividend per share |
|---|
| 2026-08-17 | $0.70 |
| 2026-05-28 | $0.60 |
| 2026-02-23 | $0.60 |
| 2025-11-17 | $0.60 |
| 2025-08-11 | $0.60 |
| 2025-05-29 | $0.50 |
| 2025-02-24 | $0.50 |
| 2024-11-18 | $0.50 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-27
- Consensus EPS estimate
- $5.93
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-28 | Jun/2026 | $5.12 |
| 2026-04-23 | - | - |
| 2026-02-25 | - | - |
| 2025-10-28 | - | - |
| 2025-07-29 | - | - |
| 2025-07-22 | - | - |
| 2025-04-23 | - | - |
| 2025-04-22 | - | - |
Filings and sources
- Company website
- chemed.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
HCA Healthcare, Inc. (HCA) · DaVita Inc. (DVA) · Universal Health Services Inc (UHS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades